Sign In
Buy SRPT
$16.24
-0.0100 (-0.0615%)
At Close: Jun 03, 2026
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates
06:51pm, Tuesday, 02'nd Aug 2022
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -147.66% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.2% Jump Turn into More Strength?
10:51am, Monday, 01'st Aug 2022
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
Why Sarepta Therapeutics Stock Is Perking Up Today
01:22pm, Friday, 29'th Jul 2022
The biotech's gene therapy for Duchenne's muscular dystrophy could hit the market sooner than expected.
Sarepta (SRPT) Stock Gains on FDA News
10:22am, Friday, 29'th Jul 2022
Source: Panuwach/Shutterstock Sarepta Therapeutics (NASDAQ: SRPT ) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment. According to the company,
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
10:03am, Wednesday, 06'th Jul 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new functional data across multiple studies from the SRP-9001 (delandistrogene moxeparvovec) program for Duchenne muscular dystrophy. SRP-9001 is an
Sarepta Has New Gene Therapy Data Coming. What It Could Mean for the Stock.
03:00am, Wednesday, 06'th Jul 2022
Sarepta will update investors Thursday on the data it hopes will persuade U.S. regulators to accelerate approval of its gene therapy treatment for muscular dystrophy.
Sarepta stock plunges after FDA puts study on hold
04:11pm, Thursday, 23'rd Jun 2022
Sarepta Therapeutics Inc. SRPT, +5.14% shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on hold by the Food and Drug Administration
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
12:49pm, Friday, 03'rd Jun 2022
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
08:30am, Thursday, 02'nd Jun 2022
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
Expert Ratings for Sarepta Therapeutics
02:07pm, Thursday, 19'th May 2022 Benzinga
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
3
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
03:37pm, Tuesday, 10'th May 2022 Zacks Investment Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
02:56pm, Tuesday, 10'th May 2022 Zacks Investment Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
10:20am, Tuesday, 10'th May 2022 Zacks Investment Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
10:20am, Friday, 06'th May 2022 Zacks Investment Research
Smart Beta ETF report for FBT
